Treatment Options for Transplant-Eligible Multiple Myeloma

EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma

EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma

EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH

EP: 4.Biggest FDA News for Multiple Myeloma in 2021

Now Viewing

EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma

EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma

EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma

EP: 8.Understanding Adverse Events in Multiple Myeloma

EP: 9.BCMA-Directed Agents for Multiple Myeloma

EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma

EP: 11.Emerging Research and Therapies for Multiple Myeloma

EP: 12.Upcoming Phase 3 Data in Multiple Myeloma

EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma

EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment

EP: 15.Current Leading Therapies for Multiple Myeloma

Nina Shah, MD: For transplant-eligible patients, there are several approaches that one can use. The most common approach right now is bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone, also known as VRd, based on the SWOG [S0777] trial [NCT00644228] from several years ago. However, it should be noted that we have greater data looking at other regimens. One of the biggest splashes that we have is the GRIFFIN [NCT02874742] data looking at daratumumab [Darzalex]–VRd. [That’s] daratumumab, bortezomib [Velcade], lenalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients. In this study, patients were randomized to get dara-RVd versus RVd with transplant included, and those patients that got into the daratumumab arm also had daratumumab-lenalidomide maintenance, or DR maintenance, for a total of 32 cycles. This was an interesting study to show that you could improve the stringent CR [complete response] rate and that had been demonstrated, so it met its primary end point.

As we get more and more data, I’m very much looking forward to this year’s ASH [Annual Meeting] to see if there’s any trend in progression-free survival. Based on the curves that we’d seen before, I’m hoping that there will be because if we understand that a [quadruplet] therapy is better than a triplet therapy, especially for very fit patients. We can extend how long patients are having that first remission. It’s so important because the most amount of time you’re going to get from success of your therapy is that first remission. I’m looking forward to that that data to becoming public.